Cargando…

A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy

OBJECTIVES: Real-time assessment of treatment response in glioblastoma (GBM) patients on immune checkpoint blockade (ICB) remains challenging because inflammatory effects of therapy may mimic progressive disease, and the temporal evolution of these inflammatory findings is poorly understood. We comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xin, Lim-Fat, Mary Jane, Qin, Lei, Li, Angie, Bryant, Annie, Bay, Camden P., Gao, Lu, Miskin, Nityanand, Liu, Zaiyi, Iorgulescu, J. Bryan, Xu, Xiaoyin, Reardon, David A., Young, Geoffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268004/ https://www.ncbi.nlm.nih.gov/pubmed/34249718 http://dx.doi.org/10.3389/fonc.2021.679331

Ejemplares similares

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023)

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2023)

The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation
por: Suter, Yannick, et al.
Publicado: (2022)

MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Evaluation of RANO Criteria for the Assessment of Tumor Progression for Lower-Grade Gliomas
por: Raman, Fabio, et al.
Publicado: (2023)

Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
por: Linhares, Paulo, et al.
Publicado: (2013)

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
por: Chukwueke, Ugonma N, et al.
Publicado: (2019)

Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria
por: Douri, Keiss, et al.
Publicado: (2023)

U(rano)topia: spectral skies and rainbow holograms for silica aerogel artworks
por: Michaloudis, Ioannis, et al.
Publicado: (2022)

Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
por: Boire, Adrienne, et al.
Publicado: (2019)

Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?
por: Imber, Brandon S, et al.
Publicado: (2019)

Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study
por: Bjorland, Line Sagerup, et al.
Publicado: (2023)

Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas
por: Moon, Hye Hyeon, et al.
Publicado: (2021)

Rapa Nui (Easter Island) Rano Raraku crater lake basin: Geochemical characterization and implications for the Ahu-Moai Period
por: Argiriadis, E., et al.
Publicado: (2021)

NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics
por: Abayazeed, Aly H, et al.
Publicado: (2022)

Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study
por: Vera, Elizabeth, et al.
Publicado: (2022)

Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment
por: Al Feghali, Karine A, et al.
Publicado: (2021)

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0
por: Law, Ian, et al.
Publicado: (2018)

PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study
por: Kaur, Manpreet, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint blockade for brain metastases
por: Harary, Maya, et al.
Publicado: (2019)

Quantifying Impact of Disruption to Radiology Education During the COVID-19 Pandemic and Implications for Future Training
por: Shi, Junzi, et al.
Publicado: (2021)

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models
por: Datta, Meenal, et al.
Publicado: (2023)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
por: Yeo, Alan T., et al.
Publicado: (2023)

Immune Checkpoints and Innovative Therapies in Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Immune Checkpoint in Glioblastoma: Promising and Challenging
por: Huang, Jing, et al.
Publicado: (2017)

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
por: ISHIKAWA, Eiichi, et al.
Publicado: (2017)

75. PROGRAMMED DEATH RECEPTOR LIGAND ONE EXPRESSION MAY INDEPENDENTLY PREDICT SURVIVAL IN NON-SMALL CELL LUNG CARCINOMA BRAIN METASTASES PATIENTS RECEIVING IMMUNOTHERAPY
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

RARE-25. DISSECTING THE CONTEMPORARY EPIDEMIOLOGY OF PRIMARY AND SECONDARY BRAIN TUMORS IN INFANCY THROUGH CHILDHOOD
por: Lamba, Nayan, et al.
Publicado: (2021)

GERM-04. PRIMARY INTRACRANIAL GERM CELL TUMORS ARE MORE PREVALENT AMONG PEDIATRIC PATIENTS OF ASIAN/PACIFIC ISLANDER RACE/ETHNICITY IN THE UNITED STATES
por: Lamba, Nayan, et al.
Publicado: (2021)

Evaluation of early imaging response criteria in glioblastoma multiforme
por: Gladwish, Adam, et al.
Publicado: (2011)

An investigation of minimisation criteria
por: Wade, Angie, et al.
Publicado: (2006)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma
por: Videla-Richardson, Guillermo A., et al.
Publicado: (2021)

Treatment options and outcomes for glioblastoma in the elderly patient
por: Arvold, Nils D, et al.
Publicado: (2014)

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
por: Ellingson, Benjamin M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v2vsigti3bnd83m03hneffoial